CF Foundation Awards Armata Up to $5M to Advance AP-PA02 to Trialhttps://cysticfibrosisnewstoday.com/2020/03/20/armata-receives-up-to-5m-from-cf-foundation-develop-phage-therapy-ap-pa02/
AP-PA02Armata
New CF Treatment Candidate AP-PA02 Targets P. Aeruginosa Infectionshttps://cysticfibrosisnewstoday.com/2019/09/16/armata-to-explore-ap-pa02-as-new-candidate-for-targeting-p-aeruginosa/
AP-PA02

Showing topic

AP-PA02
ArmataUse of bacteriophages to treat antibiotic-resistant infectionsUse of phages to treat antibiotic resistance connected to cystic fibrosis